Literature DB >> 33108969

Predicting Outcomes in Sporadic and Hereditary Medullary Thyroid Carcinoma over Two Decades.

Anupam Kotwal1,2, Dana Erickson1, Jennifer R Geske3, Ian D Hay1, M Regina Castro1.   

Abstract

Background: Medullary thyroid cancer (MTC) can be associated with significant morbidity and mortality in advanced cases. Hence, we aimed to identify factors at the time of MTC surgery that predict overall survival (OS), disease-specific survival (DSS), locoregional recurrence/persistence (LR), and distant metastases (DM).
Methods: We performed a retrospective study of clinicopathologic, radiological, and laboratory data in MTC patients who underwent thyroidectomy at Mayo Clinic from January 1995 to December 2015.
Results: We identified 163 patients (mean age 48.4 years, 48% males), 102 with sporadic MTC and 61 with hereditary disease (n = 46 multiple endocrine neoplasia [MEN] 2A, n = 3 MEN 2B, n = 12 familial MTC) with a median follow-up time of 5.5 years. On univariate analysis, age >55 years, male sex, DM at the time of surgery (M1), lateral neck lymph node (LN) involvement (N1b), gross extrathyroidal extension (ETE), American Joint Committee on Cancer (AJCC) stage 3/4, tumor size (T) 3/4, tumor size, and postoperative calcitonin (Ctn) and carcinoembryonic antigen (CEA) were significant predictors of worse OS and DSS. On multivariable analysis, both gross ETE (hazard ratio [HR] 4.62, 6.58) and M1 (HR 5.11, 10.45) remained significant predictors of worse OS as well as DSS, while age >55 years (HR 3.21), male sex (HR 2.42), and postoperative Ctn (HR 1.002 for every 100 pg/mL increase) were significant only for worse OS. On univariate analysis, male sex, M1, N1b, gross ETE, stage 3/4, T 3/4, tumor size, number of LNs involved, and postoperative Ctn were significant predictors of LR and DM; age >55 years was additionally significant for DM. On multivariable analysis, gross ETE (HR 3.16, 5.93) and N1b (HR 4.31, 4.64) remained significant predictors of LR and DM; ratio of resected/involved LN (HR 10.91) was additionally predictive for LR and postoperative Ctn (HR 1.003 for every 100 pg/mL increase) for DM. Conclusions: Disease burden at initial surgery, especially gross ETE, lateral neck LN involvement, and DM, as well as the biochemical response to surgery appear to be more important than demographic factors in terms of MTC prognosis. These findings highlight the importance of rigorous perioperative assessment to better predict MTC outcomes.

Entities:  

Keywords:  cancer recurrence; metastasis; mortality; survival; thyroid cancer; thyroidectomy

Mesh:

Year:  2020        PMID: 33108969     DOI: 10.1089/thy.2020.0167

Source DB:  PubMed          Journal:  Thyroid        ISSN: 1050-7256            Impact factor:   6.506


  6 in total

Review 1.  Roles and new Insights of Macrophages in the Tumor Microenvironment of Thyroid Cancer.

Authors:  Qi Liu; Wei Sun; Hao Zhang
Journal:  Front Pharmacol       Date:  2022-04-11       Impact factor: 5.988

Review 2.  Is Encapsulated Medullary Thyroid Carcinoma Associated With a Better Prognosis? A Case Series and a Review of the Literature.

Authors:  Andrea Contarino; Alessia Dolci; Marco Maggioni; Francesca Maria Porta; Gianluca Lopez; Uberta Verga; Francesca Marta Elli; Elisabetta Francesca Iofrida; Gianmaria Cantoni; Giovanna Mantovani; Maura Arosio
Journal:  Front Endocrinol (Lausanne)       Date:  2022-04-27       Impact factor: 6.055

Review 3.  Interaction of Gut Microbiota with Endocrine Homeostasis and Thyroid Cancer.

Authors:  Qi Liu; Wei Sun; Hao Zhang
Journal:  Cancers (Basel)       Date:  2022-05-27       Impact factor: 6.575

Review 4.  Multiple endocrine neoplasia 2: an overview.

Authors:  B Saravana-Bawan; J D Pasternak
Journal:  Ther Adv Chronic Dis       Date:  2022-02-25       Impact factor: 5.091

5.  Clinical Characteristics, Surgical Management, and Prognostic Factors of Medullary Thyroid Carcinoma: A Retrospective, Single-Center Study.

Authors:  Xin Wu; Binglu Li; Chaoji Zheng
Journal:  Technol Cancer Res Treat       Date:  2022 Jan-Dec

6.  Diagnostic characteristics, treatment patterns, and clinical outcomes for patients with advanced/metastatic medullary thyroid cancer.

Authors:  Rohan Parikh; Lisa M Hess; Elizabeth Esterberg; Naleen Raj Bhandari; James A Kaye
Journal:  Thyroid Res       Date:  2022-02-12
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.